Company: NCEL
Filing Date: 2025-01-31
Form Type: 425
Source: 0001213900-25-008564
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-01-31
Form: 425
Chunk 2
---
 are committed to working collaboratively to advance innovative solutions in biotechnology.
We aim to convene our shareholders meeting in the coming weeks to support a smooth transition toward this partnership..”

As the Merger process progresses, both companies remain focused on
aligning their efforts to become a leading force in developing therapies that address critical health challenges.

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical company, working
with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative
therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland
and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates.
For more information, please visit www.nlspharma.com.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing “off-the-shelf”,
allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells
(hESCs) into functional cells. AstroRx®, the company’s lead product, is an astrocyte cell therapy in clinical development for
the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.

IsletRx is the company’s treatment for diabetes. IsletRx is comprised
of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with
insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus
of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development
of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Safe Harbor Statement

This press release contains expressed or implied forward-looking statements
pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements when they discuss the expected
closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their respective shareholders, including
value creation for shareholders, as well as the expected strategic position of the combined company following the Merger, if completed.
These forward-looking statements and their implications are based on the current expectations